The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Kiniksa Pharmaceuticals International Plc shares valued at $542,808 were sold by Tessari Eben on Jul 14 ’25. At $28.72 per share, Tessari Eben sold 18,900 shares. The insider’s holdings dropped to 49,163 shares worth approximately $1.42 million following the completion of this transaction.
Also, Tessari Eben purchased 18,900 shares, netting a total of over 542,860 in proceeds.
Before that, Tessari Eben had sold 17,300 shares from its account. In a trade valued at $489,244, the CHIEF OPERATING OFFICER traded Kiniksa Pharmaceuticals International Plc shares for $28.28 each. Upon closing the transaction, the insider’s holdings decreased to 17,300 shares, worth approximately $1.78 million.
As published in their initiating research note from Citigroup on March 13, 2025, Kiniksa Pharmaceuticals International Plc [KNSA] has been a Buy and the price target has been revised to $40. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in mid September. As of May 03, 2024, Wells Fargo has initiated its “an Overweight” rating for KNSA. Earlier on June 29, 2020, BofA Securities resumed its rating. Their recommendation was “a Buy” for KNSA stock.
Analyzing KNSA Stock Performance
On last trading session,, Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] rose 1.48% to $28.84. The stock’s lowest price that day was $28.1861, but it reached a high of $28.91 in the same session. During the last five days, there has been a drop of approximately -0.38%. Over the course of the year, Kiniksa Pharmaceuticals International Plc shares have jumped approximately 33.46%.
Support And Resistance Levels for Kiniksa Pharmaceuticals International Plc (KNSA)
RSI (Relative Strength Index) is 55.25 on the 14-day chart, showing neutral technical sentiment.
Is Kiniksa Pharmaceuticals International Plc subject to short interest?
Stocks of Kiniksa Pharmaceuticals International Plc saw a sharp steep in short interest on 2025-06-13 dropping by -0.95 million shares to 2.36 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 3.31 million shares. A decline of -40.13% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.6 of the overall float, the days-to-cover ratio (short ratio) decline to 3.6.
Which companies own the most shares of Kiniksa Pharmaceuticals International Plc (KNSA)?
In terms of Kiniksa Pharmaceuticals International Plc share price expectations, FactSet research, analysts set an average price target of 35 in the next 12 months, up nearly 23.15% from the previous closing price of $28.42. Analysts anticipate Kiniksa Pharmaceuticals International Plc stock to reach 40 by 2025, with the lowest price target being 34. In spite of this, 1 analysts ranked Kiniksa Pharmaceuticals International Plc stock as Buy at the end of 2025. On April 01, 2020, BofA/Merrill assigned a price target of “a Buy” to the stock and initiated coverage with a $25.
